Table of Contents
- Key Points
- Why This Research Matters: The Ileocecal Valve
- Study Methods: How the Research Was Conducted
- Who Was Studied: 158 Patients Across Seven Hospitals
- Findings, Part 1: Bowel Symptoms and Quality of Life (GIQLI Questionnaire)
- Findings, Part 2: Cancer Patients' Survey Results (EORTC QLQ-CR29)
- Findings, Part 3: Vitamin B12 Blood Levels After Surgery
- Clinical Implications: What These Findings Mean for Patients
- Study Limitations: What This Research Could Not Show
- Recommendations for Patients and Doctors
- Frequently Asked Questions
- Source Information
Key Points
- In 158 patients, bowel symptoms and quality of life improved by 6 weeks after ileocecal valve removal.
- Ileocecal valve removal can raise SIBO risk to 32%, versus 0–20% in the general population.
- Patients should be warned before surgery about possible changes in bowel habits after ileocecal valve removal.
Why This Research Matters: The Ileocecal Valve
The ileocecal valve (ICV) — also called the ileocecal junction — is a small sphincter muscle that sits where the small intestine meets the large intestine. Its job is to control the one-way flow of digested food (chyme) from the ileum into the colon and to keep bacteria from backing up into the small bowel.
Surgeons often remove this valve during operations on the right side of the colon. Right colectomy (removing the right part of the colon), extended right colectomy (removing more of the colon), and ileocecal resection (removing just the valve area) are common operations. They are performed for colon cancer, for precancerous disease, and sometimes for benign conditions such as inflammation (for example, Crohn's disease) or ischemia (poor blood flow), in both planned and emergency settings.
The concern is what happens once that muscular gate is gone. Removal of the ICV can allow colon bacteria to travel backward into the ileum (small intestine). In some people, this can lead to small intestinal bacterial overgrowth (SIBO), a condition marked by an abnormal increase in bacteria in the upper gastrointestinal tract. Symptoms of SIBO are often vague: abdominal discomfort, bloating, and diarrhea. In severe cases, SIBO can cause malabsorption, malnutrition, and vitamin B12 deficiency (low vitamin B12, needed for healthy nerves and red blood cells).
The reported rate of SIBO in the general population is 0–20%, meaning up to 2 in 10 people. After ICV resection, that number climbs to 32% — roughly 1 in 3 patients. That is why patients facing this surgery frequently ask their surgeons about long-term bowel function, nutritional health, and quality of life.
One important detail about vitamin B12: the body actively absorbs this vitamin only in the terminal ileum, the very last part of the small intestine. However, a small amount can be absorbed passively (without active transport) all along the small bowel. For this reason, surgeons have long believed that removing a segment of ileum shorter than 20 cm (about 8 inches) usually does not cause vitamin B12 deficiency.
Study Methods: How the Research Was Conducted
The study was a prospective, longitudinal, observational, multicenter study. That means researchers tracked patients forward in time, without intervening, at several hospitals. Between November 2016 and May 2018, patients were enrolled at six Italian surgical centers and one Slovenian center.
Patients eligible for the study included anyone aged 16 years or older who was undergoing a right colectomy, extended right colectomy, or ileocecal resection for malignant or benign disease — in either elective or emergency circumstances. Surgery could be performed by open, laparoscopic, or robotic approach.
Certain patients were excluded:
- Those having palliative surgery (surgery meant only to relieve symptoms, not cure)
- Those with a diverting stoma (temporary bowel opening through the belly wall)
- Those with serious postoperative complications, classified as grade 3b or higher on the Clavien-Dindo scale (meaning complications requiring surgery, intensive care, or causing death)
The study was approved by the ethics committee (Protocol Number 5903, Local Ethical Committee of Trieste University Hospital), and every participant gave written informed consent.
For each patient, the researchers recorded age, gender, whether the disease was benign or malignant, the exact type of surgery, the length of the removed surgical specimen (total length, ileum length, and colon length, measured in centimeters), cancer stage according to the AJCC classification system, and whether the patient received adjuvant chemotherapy (extra treatment after surgery).
To measure bowel function and quality of life, the team used two internationally validated questionnaires:
- GIQLI (Gastrointestinal Quality of Life Index): given to all patients, at the time of surgery, 2 weeks later, and 6 weeks later. Patients rated eight items — abdominal pain, bloating, frequent bowel movements, urgent bowel movements, diarrhea, constipation, nausea, and uncontrolled stools — on a five-point scale where 0 = never, 1 = rarely, 2 = sometimes, 3 = most of the time, and 4 = all the time. Lower scores mean fewer symptoms.
- EORTC QLQ-CR29: given only to patients with cancer, at the time of surgery, 3 months later, and 6 months later. Patients rated six items — abdominal pain, bloating, unintentional gas release, stool (fecal) leakage, frequent daytime bowel movements, and frequent nighttime bowel movements — on a four-point scale where 1 = never, 2 = occasionally, 3 = most of the time, and 4 = all the time.
The researchers also collected blood samples to measure vitamin B12 at three time points: at surgery, at 3 months, and at 6 months. They considered serum vitamin B12 levels between 148 pg/mL and 980 pg/mL (picograms per milliliter) to be within normal range. They then compared vitamin B12 levels with the length of small bowel removed.
The statistics were carefully chosen. To tell the difference between a finding that is merely statistically significant and one that is also clinically meaningful, the authors used the empirical rule effect-size (ERES) method. In simple terms, a change equal to 8% of a questionnaire's scoring range was regarded as a real, noticeable difference for the patient. For each GIQLI item, that meant a change of 0.32 points. For each QLQ-CR29 item, it meant 0.24 points. They also used a linear mixed-effects (LME) statistical model to identify which patient, surgical, and cancer-related factors most influenced total scores.
Who Was Studied: 158 Patients Across Seven Hospitals
The final analysis included 158 patients. Of these, 87 (55.0%) were men and 71 (45.0%) were women. The median age was 71 years, and ages ranged from 16 to 91 years.
The main reason for surgery was malignant (cancerous) disease, reported in 149 patients (93.3%). That group included 148 colonic adenocarcinomas (the most common type of colon cancer) and 1 maltoma (a rare lymphoma of the gut). The remaining 9 patients (6.7%) had inflammatory or ischemic (reduced blood flow) disease, which is benign.
Among cancer patients, AJCC stages were distributed as follows:
- Stage 0: 21 patients (14.2%)
- Stage I: 29 patients (19.6%)
- Stage II: 52 patients (35.1%)
- Stage III: 40 patients (27.0%)
- Stage IV: 4 patients (2.7%)
- Stage not recorded: 2 patients (1.4%)
Overall, 46 patients (30.8%) received adjuvant chemotherapy after their operation.
The operations performed were:
- Right colectomy: 135 patients (85.4%). Among these, 127 (94.1%) had cancer and 8 (5.9%) had benign disease.
- Extended right colectomy: 20 patients (12.7%). All 20 had cancer.
- Ileocecal resection: 3 patients (1.9%). Two had cancer and one had benign disease.
The surgical approach matters for recovery, too. Laparoscopy (keyhole surgery) was used in 117 patients (74.1%), open surgery in 40 patients (25.3%), and robotic surgery in 1 patient (0.6%).
Specimen lengths were recorded for every surgery. The median total length of removed bowel was 31 cm (range 16–152 cm). The median length of removed ileum was 8 cm (range 2–140 cm). The median length of removed colon was 20 cm (range 4–55 cm).
Findings, Part 1: Bowel Symptoms and Quality of Life (GIQLI Questionnaire)
The GIQLI questionnaire was completed by 119 patients (75.3%) at baseline, 118 patients (74.7%) at 2 weeks, and 111 patients (70.3%) at 6 weeks. The dropout rate was 29.7%, meaning about 3 in 10 patients did not complete all three surveys. Statistical analysis was based only on patients who completed follow-up.
The key finding: symptoms improved significantly between baseline and 6 weeks for every item except uncontrolled stools. In plain terms, most patients felt better after surgery than before it, often fairly quickly.
The table below shows average scores. Remember: a lower number means fewer symptoms and better quality of life.
| Symptom (GIQLI question) | At surgery | 2 weeks | 6 weeks | p value |
|---|---|---|---|---|
| Abdominal pain (#1) | 1.73 | 1.50 | 1.35* | <0.001 |
| Bloating (#3) | 2.02 | 1.84 | 1.34* | <0.001 |
| Frequent bowel movements (#7) | 1.66 | 1.75 |
Frequently Asked Questions
Should I get a second opinion before right colectomy with ileocecal valve removal to discuss bowel function and vitamin B12 risks?
Patients facing right colectomy, extended right colectomy, or ileocecal resection often have questions about bowel habits, SIBO risk, and vitamin B12 after the valve is removed. Bowel symptoms and quality-of-life scores improved by six weeks on most GIQLI items, and no patient developed vitamin B12 deficiency, even after longer ileal resection. Surgeons still advise warning patients beforehand about possible changes in bowel habits. A second opinion can help confirm the surgical plan and clarify expected digestive and nutritional follow-up. Diagnostic Detectives Network provides independent expert second opinions.
